J I Hoare et al. 2022. Gynecol Oncol. 167(1):96-106. PMID: 35918200.
Product description:
Platinum-resistant HGSC cancer cells with a growth advantage in the presence of therapy that expand to create drug-resistant tumours.
Gender:
Female
CRISPR:
No
Production details:
Cells were cultured in vitro in increasing concentrations of either cisplatin or carboplatin until an increase in IC50 between two and ten-fold was achieved to reflect the resistance observed in human patients
Parental cell line:
OVCAR4 cell lines
Model description:
Platinum-resistant HGSC in vivo cell line
Growth medium:
DMEM containing 10% FBS and 1% penicillin/streptomycin. Cells should be cultured without drug but used at low passage to ensure drug resistance is maintained.
Temperature:
37° C
Mycoplasma free:
Yes
References:
H Hockings et al. 2022. Cancer Res. 85(18):3503-3517.PMID: 40299825
J I Hoare et al. 2022. Gynecol Oncol. 167(1):96-106. PMID: 35918200.
Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.
